Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Breast Cancer Research

Fig. 4

From: Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

Fig. 4

Serum thymidine kinase 1 (TK1) activity and tumor Ki-67 by time point and Ki-67 response category for individual patients. TK (top panel) and Ki-67 (lower panel) levels in logarithmic scale over time for individual patients are shown in the line graphs. TK activity and Ki-67 from the same patient are denoted by the same line color. Palbociclib (Palbo) significantly reduced serum TK activity 2 weeks after initiation in the anastrozole-sensitive or palbociclib-sensitive group by Ki-67. Palbo washout led to a significant increase in serum TK at the time of surgery. * p < 0.05, ** p < 0.01, *** p < 0.001. Filled triangles denote the average of TK or Ki-67 from different patients at the corresponding time points

Back to article page